JCT  Vol.5 No.12 , October 2014
A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting
Abstract: Background: Following approval of ipilimumab, this observational cohort study (CA184-332) was initiated to describe patient and disease characteristics, patterns of care, survival, and adverse events (AEs) in advanced melanoma (AM) patients treated with first-line ipilimumab in realworld US community practice. Methods: Adult patients with treatment-naive AM who received ≥1 dose of ipilimumab 3 mg/kg between April 2011 and September 2012 were retrospectively identified at US Oncology sites. Clinical data were abstracted from patient medical records. Results: Median age of the 157 patient cohorts was 66 years (range 21 - 91). 68.2% were male, and 90.5% had a cutaneous primary site. At ipilimumab initiation, 80.9% of patients had an ECOG performance status of 0 or 1; 54.1% were stage M1c; 34.4% had brain metastases; 24.8% had elevated lactate dehydrogenase, and 13.4% were positive for BRAF mutation. All 4 cycles of ipilimumab were completed by 55.8% of patients. At a median follow-up of 8.5 months (range 2.9 - 15.0), median overall survival was 11.5 months (95% CI: 8.9 - 16.6) and 1-year survival was 46.7% (95% CI: 38.1 - 54.9). During ipilimumab treatment, AEs were experienced by 63.7% of patients. The most frequent AEs were gastrointestinal (41.4%; diarrhea in 19.1%) and skin-related (28.0%; rash in 17.8%); 17.8% of patients had an AE that led to ipilimumab discontinuation. Conclusions: These real-world results are consistent with those from clinical trials and provide evidence supporting the effectiveness and safety of first-line ipilimumab 3 mg/kg monotherapy in patients with AM treated in a community practice setting.
Cite this paper: Patt, D. , Rembert, D. , Bhor, M. , Bhowmik, D. and Rao, S. (2014) A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting. Journal of Cancer Therapy, 5, 1049-1058. doi: 10.4236/jct.2014.512110.

[1]   American Cancer Society (2014) American Cancer Society: Cancer Facts & Figures 2014. American Cancer Society, Atlanta.

[2]   Surveillance Epidemiology and End Results: Cancer Statistics.

[3]   Korn, E.L., Liu, P.Y., Lee, S.J., Chapman, J.A., Niedzwiecki, D., Suman, V.J., et al. (2008) Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. Journal of Clinical Oncology, 26, 527-534.

[4]   Garbe, C., Eigentler, T.K., Keilholz, U., Hauschild, A. and Kirkwood, J.M. (2011) Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. The Oncologist, 16, 5-24.

[5]   Hodi, F.S., O’Day, S.J., McDermott, D.F., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363, 711-723.

[6]   Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., et al. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 364, 2517-2526.

[7]   Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 364, 2507-2516.

[8]   Weber, J.S., Kahler, K.C. and Hauschild, A. (2012) Management of Immune-Related Adverse Events and Kinetics of Response with Ipilimumab. Journal of Clinical Oncology, 30, 2691-2697.

[9]   Hersh, E.M., O’Day, S.J., Powderly, J., Khan, K.D., Pavlick, A.C., Cranmer, L.D., et al. (2011) A Phase II Multicenter Study of Ipilimumab with or without Dacarbazine in Chemotherapy-Na?ve Patients with Advanced Melanoma. Investigational New Drugs, 29, 489-498.

[10]   Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., et al. (2011) A Prospective Phase II Trial Exploring the Association between Tumor Microenvironment Biomarkers and Clinical Activity of Ipilimumab in Advanced Melanoma. Journal of Translational Medicine, 9, 204.

[11]   Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. (2013) Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Metastatic or Locally Advanced, Unresectable Melanoma. European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, 27 September-1 October 2013, Abstract LBA 24.

[12]   Damsky, W.E., Rosenbaum, L.E. and Bosenberg, M. (2010) Decoding Melanoma Metastasis. Cancers, 3, 126-163.

[13]   Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. (2012) Ipilimumab in Patients with Melanoma and Brain Metastases: An Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 459-465.

[14]   Di Giacomo, A.M., Ascierto, P.A., Pilla, L., Santinami, M., Ferrucci, P.F., Giannarelli, D., et al. (2012) Ipilimumab and Fotemustine in Patients with Advanced Melanoma (NIBIT M1): An Open-Label, Single-Arm Phase 2 Trial. The Lancet Oncology, 13, 879-886.

[15]   Jang, S. and Atkins, M.B. (2013) Which Drug, and When, for Patients with BRAF-Mutant Melanoma? The Lancet Oncology, 14, e60-e69.

[16]   Ackerman, A., Klein, O., McDermott, D.F., Wang, W., Ibrahim, N., Lawrence, D.P., et al. (2014) Outcomes of Patients with Metastatic Melanoma Treated with Immunotherapy Prior to or after BRAF Inhibitors. Cancer, 120, 1695-1701.

[17]   Ascierto, P.A. and Margolin, K. (2014) Ipilimumab before BRAF Inhibitor Treatment May Be More Beneficial than Vice Versa for the Majority of Patients with Advanced Melanoma. Cancer, 120, 1617-1619.

[18]   Margolin, K.A., Wong, S.L., Penrod, J.R., Song, J., Chang, I.F., Johnson, D.B., et al. (2013) Effectiveness and Safety of First-Line Ipilimumab 3 mg/kg Therapy for Advanced Melanoma: Evidence from a US Multisite Retrospective Chart Review. European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, 27 September-1 October 2013, Abstract 3742.